Serina Therapeutics Unveils Breakthrough in LNP Technology

An update from Serina Therapeutics ( (SER) ) is now available.

On April 15, 2025, Serina Therapeutics announced that its Chief Development Officer, Dr. Randall Moreadith, presented at the LNP Formulation & Process Development Summit in Boston. The presentation highlighted a significant advancement in lipid nanoparticle (LNP) technology, where the company has identified a PEOZ-lipid capable of replacing the PEG-lipid in standard LNP formulations. This breakthrough addresses the high incidence of anaphylaxis associated with PEG-lipids in mRNA vaccines and other therapies, potentially improving safety and efficacy for patients.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, SER is a Neutral.

Serina Therapeutics’ overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. Although there is some short-term technical momentum, the valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.

To see Spark’s full report on SER stock, click here.

More about Serina Therapeutics

Serina Therapeutics is a biotechnology company focused on developing innovative drug delivery systems, including small molecules, lipid nanoparticles, and antibody drug conjugates. The company is known for its POZ Platform® for programmable drug delivery, which aims to enhance the treatment of multiple therapeutic indications.

YTD Price Performance: 4.27%

Average Trading Volume: 12,127

Technical Sentiment Signal: Buy

Current Market Cap: $52.82M

For a thorough assessment of SER stock, go to TipRanks’ Stock Analysis page.